Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer

Avishay Sella, Tal Sella, Avivit Peer, Raanan Berger, Stephen Jay Frank, Eli Gez, David Sharide, Henry Hayat, Ekaterina Hanovich, Svetlana Kovel, Eli Rosenbaum, Victoria Neiman, Daniel Keizman

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

31 اقتباسات (Scopus)

ملخص

The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) inmetastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence.We retrospectively demonstrated a prostate-specific antigen (PSA) response of 31.5%, partial response of 15.3%, and median survival of 8.2 months with CAB. CAB was active after AA and docetaxel in mCRPC. Patients and Methods: One hundred thirty mCRPC patients received AA after docetaxel treatment in compassionate programs. Of them, 24 (18.4%) subsequently received CAB. We retrospectively reviewed their data using conventional methods. Results: Twenty-four patients received a median of 4 (range, 1-13) CAB cycles. Nineteen (79.1%) of them received primary prophylaxis with growth factors. Median patient characteristics were: age 65 (range, 57-85) years; Gleason score: 8 (range, 6-10); and PSA: 128.1 (range, 0.01-1700) ng/mL. A PSA response (≥ 50% decrease from baseline) occurred in 6 (31.5%) of 19 evaluable patients (95% confidence interval [CI], 11.8-54.2%). CAB therapy obtained a partial response in 2 of the 13 (15.3%) evaluable patients (95% CI, 2.9-45.4%). Median survival from initiation of CAB was 8.2 (95% CI, 3.34-13.05) months, from AA 16.1 (95% CI, 11.56-20.64) and from docetaxel 32.0 (95% CI, 11.56-39.69). Conclusion: A limited number of patients with mCRPC received CAB after docetaxel and AA treatment. In this selected population, CAB was active.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)428-432
عدد الصفحات5
دوريةClinical Genitourinary Cancer
مستوى الصوت12
رقم الإصدار6
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - 2014
منشور خارجيًانعم

بصمة

أدرس بدقة موضوعات البحث “Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا